![Congenica Receives CE Mark for Genomic Analysis Software](https://blog.congenica.com/hs-fs/hubfs/Canva%20images/Congenica%20is%20now%20a%20CE%20Marked%20medical%20device.png?width=320&height=192&name=Congenica%20is%20now%20a%20CE%20Marked%20medical%20device.png)
Congenica Receives CE Mark for Genomic Analysis Software
Congenica NGS data analysis software for genomic data interpretation is now CE marked under the In Vitro Diagnostics Directive.
![David Atkins welcomes the Government's Life Sciences Sector Vision](https://blog.congenica.com/hs-fs/hubfs/Dr%20Meriel%20McEntagart,%20Consultant%20Geneticist,%20St%20George%E2%80%99s%20University%20Hospitals%20NHS%20%283%29.png?width=320&height=192&name=Dr%20Meriel%20McEntagart,%20Consultant%20Geneticist,%20St%20George%E2%80%99s%20University%20Hospitals%20NHS%20%283%29.png)
David Atkins welcomes the Government's Life Sciences Sector Vision
A press release from the UK Bio Industry Association (BIA) welcomes the Government's new Life Sciences Sector Vision and quotes Congenica CEO David Atkins
![Clinical OMICs interview with David Atkins CEO Congenica](https://blog.congenica.com/hs-fs/hubfs/CEO%20David%20Atkins%20is%20inteviewed%20for%20Clinical%20OMICs.png?width=320&height=192&name=CEO%20David%20Atkins%20is%20inteviewed%20for%20Clinical%20OMICs.png)
Clinical OMICs interview with David Atkins CEO Congenica
Clinical OMICs features an interview with Congenica CEO David Atkins who talks about the genomic medicine landscape and Congenica's plans for the future.
![Congenica funded to reduce fatal drug interactions by mapping genes](https://blog.congenica.com/hs-fs/hubfs/Blog%20Congenica%20awarded%20%C2%A32%20million%20to%20develop%20new%20pharmacogenetics%20software%20to%20prevent%20fatal%20drug%20interactions.png?width=320&height=192&name=Blog%20Congenica%20awarded%20%C2%A32%20million%20to%20develop%20new%20pharmacogenetics%20software%20to%20prevent%20fatal%20drug%20interactions.png)
Congenica funded to reduce fatal drug interactions by mapping genes
New software to reduce the number of adverse drug reactions is being developed thanks to a joint investment of £2 million provided by UKRI and L& G.
![Congenica named in UK’s Digital Health Playbook - ‘First 100’ Companies](https://blog.congenica.com/hs-fs/hubfs/Canva%20images/Canva%20Design%20DAEftBO8myc.png?width=320&height=192&name=Canva%20Design%20DAEftBO8myc.png)
Congenica named in UK’s Digital Health Playbook - ‘First 100’ Companies
Congenica has been featured in the UK’s Digital Health Playbook ‘First 100’ as one of the UK’s most innovative and impactful digital health companies.
![Genome UK implementation plan](https://blog.congenica.com/hs-fs/hubfs/Canva%20images/Canva%20Design%20DAEfFfyYnyY.png?width=320&height=192&name=Canva%20Design%20DAEfFfyYnyY.png)
![Congenica 3.1 - Automating best practices in variant interpretation](https://blog.congenica.com/hs-fs/hubfs/Integrated-genome-browser-1.png?width=320&height=192&name=Integrated-genome-browser-1.png)
Congenica 3.1 - Automating best practices in variant interpretation
Congenica 3.1 release forms part of our ongoing commitment to embedding variant analysis best practices in an automated platform and intuitive workflow.
![Congenica assures the clinical safety of NHS genomic analysis](https://blog.congenica.com/hs-fs/hubfs/Canva%20images/DCB0129%20Clinical%20Risk%20Management%20its%20Application%20in%20the%20Manufacture%20of%20Health%20IT%20Systems.png?width=320&height=192&name=DCB0129%20Clinical%20Risk%20Management%20its%20Application%20in%20the%20Manufacture%20of%20Health%20IT%20Systems.png)
Congenica assures the clinical safety of NHS genomic analysis
Congenica clinical decision support and NGS data analysis provides a complete Clinical Risk Management Process in compliance with the DCB0129 standard
![Congenica and Camtech Diagnostics agree strategic partnership to support genomic analysis expansion in Asia](https://blog.congenica.com/hs-fs/hubfs/Canva%20images/Canva%20Design%20DAEbc2RvwiQ.png?width=320&height=192&name=Canva%20Design%20DAEbc2RvwiQ.png)
Congenica and Camtech Diagnostics agree strategic partnership to support genomic analysis expansion in Asia
Camtech will market, distribute, sell Congenica rapid NGS data analysis software and clinical decision support in Singapore, Malaysia, Japan, South Korea
![Making information about genomic medicine accessible to all](https://blog.congenica.com/hs-fs/hubfs/alastair_kent.png?width=320&height=192&name=alastair_kent.png)
Making information about genomic medicine accessible to all
Article by: Alastair Kent OBE FRSA, Chair of the Congenica Patient Advocacy Advisory Board and former Executive Director of Genetic Alliance UK.
![Congenica Appoints Jayesh Pankhania as Chief Financial Officer](https://blog.congenica.com/hs-fs/hubfs/Canva%20images/It%20is%20exciting%20to%20join%20at%20such%20a%20pivotal%20time.png?width=320&height=192&name=It%20is%20exciting%20to%20join%20at%20such%20a%20pivotal%20time.png)
Congenica Appoints Jayesh Pankhania as Chief Financial Officer
Digital health company Congenica, providing rapid and accurate genomic data analysis software, appoints new Chief Financial Officer, Jayesh Pankhania.
![Institute of Immunology and Genetics in Kaiserslautern selects Congenica to accelerate its whole exome sequencing](https://blog.congenica.com/hs-fs/hubfs/Anne-Karin%20Kahlert_%20Kaiserslautern.jpg?width=320&height=192&name=Anne-Karin%20Kahlert_%20Kaiserslautern.jpg)
Institute of Immunology and Genetics in Kaiserslautern selects Congenica to accelerate its whole exome sequencing
Congenica announces a new contract with the Institute of Immunology and Genetics, a leading molecular genetic laboratory in Kaiserslautern, Germany